Introduction
Telangiectatic osteosarcoma (TOS) is a rare, high-grade malignant variant of osteosarcoma, typically manifesting in the metaphysis of long bones in adolescents. Characterized by large, blood-filled cystic spaces, it often presents a diagnostic challenge due to its resemblance to benign lesions like Aneurysmal Bone Cysts (ABC). When TOS occurs in the spine—representing a mere 0.08% of primary osteosarcomas—the complexity of the anatomy further complicates early detection and surgical management.
Case Presentation
A 44-year-old woman presented with a two-month history of worsening chest and back pain, accompanied by lower limb numbness and incomplete paralysis. Initial conservative treatment for "low back pain" was ineffective. Subsequent imaging revealed significant osteolytic destruction at the T10 vertebra.
The patient underwent a Tomita type III resection, involving complete vertebral removal and spinal canal decompression, followed by intervertebral titanium mesh fusion. Histopathological analysis confirmed the diagnosis of TOS, showing vascular proliferation and malignant stromal cells. Immunohistochemistry revealed P53 positivity and a high Ki-67 proliferation index.
Despite an initially successful surgical outcome that restored her mobility, the patient experienced a rapid recurrence within three months. Complications necessitated further surgery, during which a significant hematoma was discovered. Her condition deteriorated rapidly following the development of pulmonary metastases, leading to her death six months after the initial diagnosis.
Discussion and Key Insights
The "Empty Shell" Trap
On CT imaging, spinal TOS may present with an "empty shell sign," where the bony cortex remains relatively intact despite internal destruction. This can lead clinicians to underestimate the tumor's aggressive nature compared to conventional osteosarcomas that exhibit more obvious bone formation.
Vascular Mimicry and Resistance
The study hypothesizes that TOS cells may engage in "vascular mimicry," forming their own fluid-conducting channels. This process might be exacerbated by traditional chemotherapy, potentially selecting for resistant clones and contributing to the poor prognosis observed in spinal cases. The mean survival for spinal TOS is approximately 16.4 months, significantly lower than the 68% five-year survival rate seen in long-bone varieties.
Risks of Mechanical Dissemination
The rapid recurrence post-resection suggests that even "En-bloc" surgeries may inadvertently cause "microtumor thrombolysis," spreading malignant cells through the cerebrospinal fluid. This highlights the need to evaluate neoadjuvant (preoperative) chemotherapy to stabilize the tumor before surgical intervention.
Conclusion
Spinal telangiectatic osteosarcoma remains an exceptionally aggressive malignancy with a dismal prognosis. This case underscores the necessity for heightened clinical awareness, particularly in older patients presenting with atypical spinal lesions. Future management strategies should focus on molecular profiling to identify specific genetic drivers and exploring targeted therapies to combat vascular mimicry and chemotherapy resistance.
Summary updated